Publicaciones en colaboración con investigadores/as de National Cancer Center Hospital (9)

2024

  1. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119

    Journal of Pathology: Clinical Research, Vol. 10, Núm. 3

  2. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

    Nature Medicine, Vol. 30, Núm. 8, pp. 2208-2215

2023

  1. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

    European Journal of Cancer, Vol. 195

  2. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 6, Núm. 11, pp. e2342107

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 499-511

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

  4. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond

    Expert Opinion on Biological Therapy, Vol. 21, Núm. 7, pp. 811-824

2020

  1. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 7, pp. 610-621